Medical Editor: John P. Cunha, DO, FACOEP
Librium (chlordiazepoxide) is a benzodiazepine used to treat anxiety disorders or alcohol withdrawal. Librium is available in generic form. Common side effects of Librium include:
- blurred vision,
- skin rash,
- irregular menstrual periods, or
Tell your doctor if you have side effects of Librium including:
- slurred speech,
- trouble walking,
- facial or muscle twitching,
- sleep disturbances,
- trouble urinating,
- changes in sex drive, or
- jaundice (yellowing of the skin or eyes).
The dose of Librium varies depending on the condition being treated. For mild to moderate anxiety, 5 mg or 10 mg, 3 or 4 times daily. For severe anxiety, 20 mg or 25 mg, 3 or 4 times daily. Consult your doctor for pediatric or geriatric dosing. Librium may interact with barbiturates, blood thinners, MAO inhibitors, medicine to treat psychiatric disorders, narcotics, or antidepressants. Tell your doctor all medications you use. Librium is not recommended for use during pregnancy due to the potential for harm to a fetus. Based on information from related drugs, this drug may pass into breast milk and may have undesirable effects on a nursing infant. Breastfeeding while using this medication is not recommended. Withdrawal symptoms may occur if you suddenly stop taking this medication.
Our Librium (chlordiazepoxide) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:
- depressed mood, thoughts of suicide or hurting yourself;
- restless muscle movements in your eyes, tongue, jaw, or neck;
- hyperactivity, agitation, hostility;
- hallucinations; or
- jaundice (yellowing of the skin or eyes).
Less serious side effects may include:
- drowsiness, tiredness;
- skin rash;
- nausea, vomiting, constipation; or
- irregular menstrual periods.
This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.
Read the entire detailed patient monograph for Librium (Chlordiazepoxide)
The necessity of discontinuing therapy because of undesirable effects has been rare. Drowsiness, ataxia and confusion have been reported in some patients particularly the elderly and debilitated. While these effects can be avoided in almost all instances by proper dosage adjustment, they have occasionally been observed at the lower dosage ranges. In a few instances syncope has been reported.
Other adverse reactions reported during therapy include isolated instances of skin eruptions, edema, minor menstrual irregularities, nausea and constipation, extrapyramidal symptoms, as well as increased and decreased libido. Such side effects have been infrequent, and are generally controlled with reduction of dosage. Changes in EEG patterns (low-voltage fast activity) have been observed in patients during and after Librium (chlordiazepoxide) treatment.
Blood dyscrasias (including agranulocytosis), jaundice and hepatic dysfunction have occasionally been reported during therapy. When Librium (chlordiazepoxide) treatment is protracted, periodic blood counts and liver function tests are advisable.
Withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. The more severe withdrawal symptoms have usually been limited to those patients who had received excessive doses over an extended period of time. Generally milder withdrawal symptoms (eg, dysphoria and insomnia) have been reported following abrupt discontinuance of benzodiazepines taken continuously at therapeutic levels for several months. Consequently, after extended therapy, abrupt discontinuation should generally be avoided and a gradual dosage tapering schedule followed. Addiction-prone individuals (such as drug addicts or alcoholics) should be under careful surveillance when receiving chlordiazepoxide or , other, psychotropic agents because of the predisposition of such patients to habituation and dependence.
Read the entire FDA prescribing information for Librium (Chlordiazepoxide)
© Librium Patient Information is supplied by Cerner Multum, Inc. and Librium Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.